【达仁堂：拟转让中美天津史克制药有限公司12%股权 影响公司当期投资收益约15.4亿元】金十数据4月15日讯，达仁堂公告称，公司拟分别向赫力昂（中国）有限公司、Haleon CHSARL转让所持有的中美天津史克制药有限公司4.6%股权、7.4%股权，交易价格分别为6.22亿元、10.01亿元。经初步测算，该交易预计影响公司当期投资收益约15.4亿元。本次转让完成后，公司不再持有天津史克股权。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.